Tesmilifene

Drug Profile

Tesmilifene

Alternative Names: DPPE; YMB-1002

Latest Information Update: 11 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CancerCare Manitoba; University of Manitoba
  • Developer Shin Poong Pharmaceutical; YM BioSciences
  • Class Antineoplastics; Phenyl ethers; Small molecules
  • Mechanism of Action Estrogen receptor antagonists; Histamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Gastric cancer; Prostate cancer

Most Recent Events

  • 02 Feb 2007 YM BioSciences terminates a worldwide pivotal phase III trial (DEC) in advanced Breast cancer
  • 21 Dec 2006 YM Biosciences and TTY Biopharm agree to co-develop tesmilifene for Liver cancer in Taiwan
  • 05 Jun 2006 Phase-II clinical trials in combination with docetaxel in patients with metastatic Breast Cancer in Europe and USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top